Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive Areas
Authors:
- Niccolò GoriNGNiccolò Gori
- Marco GalluzzoMGMarco Galluzzo
- Andrea ChiricozziACAndrea Chiricozzi
- Teresa GriecoTGTeresa Grieco
- Camilla ChelloCCCamilla Chello
- Filomena RussoFRFilomena Russo
- Ersilia TolinoETErsilia Tolino
- Flavia PigliacelliFPFlavia Pigliacelli
- Anna Maria MazzottaAMAnna Maria Mazzotta
- Marina TalamontiMTMarina Talamonti
- Claudia PaganiniCPClaudia Paganini
- Giacomo CaldarolaGCGiacomo Caldarola
- 23 April 2025
- journal article
- Published by S. Karger AG in Dermatology
- Vol. 241 (3) , 223-229
Abstract
Introduction: The treatment of atopic dermatitis (AD) affecting sensitive areas (head and neck, hands, and genitalia) remains a significant challenge, even with the advent of the current range of biologic therapies. Upadacitinib, a selective inhibitor of the JAK1 enzyme, showed promising results in the treatment of AD located in sensitive areas in clinical trials. The aim of this multicenter observational study was to better characterize the effectiveness of upadacitinib in sensitive areas, using specific clinimetric tools. Methods: In this multicenter observational retrospective and prospective study, we enrolled 74 adult patients (41 women and 37 men, with a mean age of 33.8 years), affected by moderate to severe AD with the involvement of at least one sensitive area, treated with upadacitinib with at least 16 weeks. Results: Over the course of the 52-week study period, upadacitinib demonstrated remarkable efficacy in the reduction of AD symptoms and associated clinical manifestations in sensitive areas. Conclusion: Our study demonstrates a significant benefit for patients with AD affecting sensitive areas when treated with upadacitinib, supporting its use first-line therapeutic choice for this specific subset of patients.Keywords
This publication has 19 references indexed in Scilit:
- Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi ConsensusDermatology and Therapy, 2024
- Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic DermatitisAdvances in Therapy, 2024
- Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of ObservationAmerican Journal of Clinical Dermatology, 2023
- Head and neck atopic dermatitis: still a challenging manifestation in the biologic eraExpert Opinion on Biological Therapy, 2023
- Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohortJournal of the American Academy of Dermatology, 2023
- Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatmentClinical and Experimental Dermatology, 2023
- Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitisExpert Opinion on Drug Metabolism & Toxicology, 2022
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsThe Lancet, 2021
- Real‐world prevalence and burden of genital eczema in atopic dermatitis: A multicenter questionnaire‐based studyThe Journal of Dermatology, 2021
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001